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Abstract
BACKGROUND/AIMS: Host genetic factor and hepatic
fibrosis may predispose to risk for hepatocellular
carcinoma (HCC). This study aimed to assess the as-
sociation between tumor necrosis factor (TNF) A poly-
morphism and hepatic fibrosis, and risk for HCC.
METHODS: One hundred eight pairs of gender-matched
and age-matched patients with HCC and unrelated healthy
controls were genotyped for TNF308.2 and TNF238.2 al-
leles with polymerase chain reaction and direct sequenc-
ing. RESULTS: The frequency of TNF308.1/TNF308.2
genotype in cases was higher than that in controls
[odds ratio (OR) = 4.37]. Multivariate analysis indicated
that TNF308.2 allele (OR = 3.23), hepatitis B surface
antigen (OR = 17.17), and antibodies to hepatitis C virus
(OR = 45.52) were independent risk factors for HCC.
Surrogate markers for significant fibrosis implied that
cases with the TNF308.2 allele have more advanced liver
fibrosis. Moreover, multivariate analysis indicated that
cirrhosis with Child-Pugh grade C, low serum albumin,
and low platelet count were independent risk factors for
carrying the TNF308.2 allele. CONCLUSIONS: TNF308.2
allele carriage and chronic hepatitis B virus/hepatitis C
virus infection are independent risk factors for HCC.
Carriage of the TNF308.2 allele correlates with disease
severity and hepatic fibrosis, which may contribute to a
higher risk for HCC.
Neoplasia (2007) 9, 987–992
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Introduction
Hepatocellular carcinoma (HCC) ranks as the fifth most com-
mon cancer in the world [1,2]. Hepatocarcinogenesis is a
multistep process with a multifactorial etiology. Chronic in-
fection with hepatitis B virus (HBV) and hepatitis C virus (HCV),
and cirrhosis of any etiology are the major risk factors for HCC
[1–8]. Overall, 75% to 80% of HCC cases are attributable
to persistent viral infections with either HBV (50–55%) or
HCV (25–30%) [1–8]. It is known that cytokines and cytotoxic
T lymphocytes are among the predominant mechanisms of host
defense against chronic HBV/HCV infection [9–11]. They can
induce an inflammatory response that often leads to chronic liver
injury [8–13].
Hepatocyte damage elicits an inflammatory response through
activation of tissue macrophage Kupffer cells. These activated
cells release an array of cytokines, including tumor necrosis fac-
tor (TNF) a, transforming growth factor-b, platelet-derived growth
factor, and other factors that act on hepatic stellate cells that
contribute to fibrogenesis [8,9,11,12]. Among antiviral cytokines,
TNF-a plays a pivotal role in host immune response to HBV/HCV
infection. Circulating TNF-a level increases during HBV [11–15]
and HCV infection [11,16–19]. An increased TNF-a level corre-
lates with the severity of hepatic inflammation, fibrosis, and tis-
sue injury [11,15,16,20]. Persistent immune-mediated hepatic
injury can initiate the process of fibrosis, cirrhosis, and, eventu-
ally, HCC [6,8–11].
The capacity for cytokine production in an individual has a
major genetic component, and there exist striking differences
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among individuals in terms of their ability to produce cyto-
kines, which have been ascribed to single-nucleotide poly-
morphism (SNP) within the coding and regulatory regions of
cytokine genes [21,22]. TNF-a expression is tightly con-
trolled at the transcriptional and posttranscriptional levels
[23,24]. Several biallelic polymorphisms have been de-
scribed within the TNF-a gene. Of particular interest are two
biallelic SNPs at the 238 or 308 position. These SNPs
result in two allelic forms. The presence of guanine defines
the common variant TNF1 allele, and the presence of ade-
nine defines the less common variant TNF2 allele [24,25].
Both SNPs have been shown to influence TNF-a expression.
TNF308.2 allele leads to an increased constitutive and induc-
ible expression of TNF-a [23,24]. TNF308.2 SNP has been
linked with several inflammatory, autoimmune, infectious, and
malignant diseases [21,22]. The functional consequences for
TNF238.2 allele are not yet clear. It also increases disease
susceptibility [26].
Fibrosis is the result of chronic liver injury regardless of
etiology [11,27–35]. Serial liver biopsies are the current gold
standard for evaluating the progression of fibrosis. However,
the procedure is limited by its invasive nature, expense, mor-
bidity, intraobserver and interobserver variabilities, and sam-
pling errors [28]. To date, several routine laboratory tests,
single or in combination, have been used as surrogate mark-
ers for predicting significant hepatic fibrosis. These tests in-
clude platelet count [28–33], cirrhosis discriminant score (CDS)
[33], aspartate aminotransferase/platelet ratio index (APRI)
[28,31,33,34], age–platelet index (AP index) [32,33,35], pro-
thrombin time [35], and age [29,32,33,35]. These parameters
confirm a positive correlation with liver fibrosis, which can be
useful in predicting the progression of chronic liver disease.
Among these, platelet count has been reported to demon-
strate the strongest correlation with hepatic fibrosis and dis-
ease severity [30–33,35]. It has been demonstrated that
low platelet count is predictive of the development of HCC
[36,37]. This information suggests that advanced fibrosis
may predispose to HCC.
Initially proposed to have anticarcinogenic effects, TNF-a
has been shown later to be tumorigenic and to act as a tu-
mor promoter [38,39]. We speculated that TNF SNP may
increase the risk for HCC through enhanced hepatic fibrosis.
We embarked on this case–control study to provide a more
precise assessment of the hypothesis.
Patients and Methods
Study Population
One hundred eight consecutive newly diagnosed patients
with HCC were enrolled as a case group. During the same
study period, 108 unrelated healthy community residents who
entered the hospital for health checkup were enrolled as a
control group. Each healthy control was pair-matched by
gender and age (± 5 years) to a patient with HCC. These
subjects were hospitalized or had visited outpatient clinics at
the Kaohsiung Medical University Hospital from January
2001 to December 2001.
Patients with HCC were eligible for the study if they were
newly diagnosed by aspiration cytology or biopsy and were
free from any known diseases with a genetic predisposi-
tion. The tumor was staged according to the tumor–node–
metastasis system [40]. Cirrhosis was diagnosed with liver
biopsy, abdominal sonography, and biochemical evidence
of parenchymal damage plus endoscopic esophageal or
gastric varices [41,42]. Patients with cirrhosis were classi-
fied into the three Child-Pugh grades based on their clinical
status [43]. There was no space-occupying lesion in the liver
in any healthy control, as evidenced by normal abdominal
sonography. None of the controls had symptoms, signs, or
biochemical evidence (including aminotransferase levels)
of liver disease, known medical illness, or hereditary disor-
ders at recruitment. All studied subjects were proved not
to have other cancers at the initial screening examination.
All study subjects were Han Chinese. Signed informed con-
sent forms were obtained from all study subjects. The study
was approved by the Investigation and Ethics Committee of
the hospital.
DNA Extraction
Genomic DNA was isolated from EDTA preserved
whole blood by standard protein K digestion and phenol–
chloroform methods.
Serologic Examination
Hepatitis B surface antigen (HBsAg) and antibodies to
hepatitis C virus (anti-HCV) were detected by Ausria-II and
second-generation Abbott HCV EIA (Abbott Laboratories,
North Chicago, IL), respectively. For anti-HCV, reactive spec-
imens were retested. Only repeatedly reactive specimens
were interpreted as anti-HCV–positive. Conventional liver
function tests were measured by an autoanalyzer (Model
736; Hitachi, Tokyo, Japan). Peripheral blood platelet count
and prothrombin time (expressed as international normalized
ratio) were routinely determined in the clinical laboratory.
Polymorphism Genotyping
For TNF308 and TNF238 genotyping, we modified the
methods described previously [26]. Briefly, a 328-bp frag-
ment spanning positions 396 to 69 of the 5V-untranslated
region of the TNF-a gene was amplified using primers
TNF396 (5V-TTCCTGCATCCGTCTGGAA-3V) and TNF69
(5V-CAGCGGAAAACTCCTTGGT-3V). Amplification was per-
formed in a thermocycler (GeneAmp 9700; Perkin Elmer,
Norwalk, CT) with 100 ng of genomic DNA, 25 pM of each
primer, 200 mM total dNTP, 1.5 mM MgCl2, standard poly-
merase chain reaction (PCR) buffer, and 2 U of Taq poly-
merase (Perkin Elmer). The following cycling conditions
were used: 60 seconds at 94jC, 60 seconds at 55jC, and
60 seconds at 72jC for 25 cycles. For SNP determination,
direct sequencing of the entire 328-bp fragment was per-
formed. The PCR product and either sense or antisense
PCR primer were determined, and the Big Dye Terminator
Cycle Sequencing Ready Reaction (PE Applied Biosystems,
Foster City, CA) was performed, followed by detection on an
ABI Prism DNA sequencer (PE Applied Biosystems). This
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led to the identification of heterozygous and homozygous
individuals for each of the four polymorphisms (TNF238.1,
TNF238.2, TNF308.1, and TNF308.2 alleles).
Surrogate Markers for Hepatic Fibrosis
From routine laboratory data, surrogate markers associ-
ated with fibrosis, including platelet count, AP index, CDS, and
APRI, were calculated exactly as originally described [31–33].
The selected cutoff values for significant fibrosis (AP index z
6; CDS z 8; APRI z 1.5; platelet count < 150  109 l1) were
adapted from Lackner et al. [33].
Statistical Analysis
Continuous variables were expressed as medians (with
ranges in parentheses), whereas categorical variables were
expressed as numbers (percentages). The difference between
the medians of continuous variables was compared using
Mann-Whitney U test. Categorical variables were compared
using chi-square test with Yates correction or Fisher’s exact
test, where appropriate. Mantel extension test for trend was
used to examine the dose–response relationship for risk
estimates of various combinations of risk factors. Odds ratio
(OR) with 95% confidence interval (95% CI) was used to es-
timate causal relations between risk factors and exposure.
Conditional logistic regression analysis was used for multi-
variate analysis. Unconditional stepwise logistic regression
analysis was used to estimate risk factors for carrying the
TNF308.2 allele in HCC patients. Adjusted OR and 95% CI
were derived from logistic regression coefficients to provide
an estimate of the statistical association between a given
variable and the disease (HCC), with the other variables held
constant. Two-tailed P values and 95% CI were given where
appropriate. An a of .05 was used as an indicator of statisti-
cal significance. In the genotyping of TNF-a, the P value was
corrected for the number of comparisons at each locus (Pc)
according to Bonferroni correction. In each group, the distri-
bution of TNF-a genotypes was tested for deviation from
the Hardy-Weinberg equilibrium using goodness-of-fit chi-
square test.
Results
Demographic Information of Cases and Controls
The demographic characteristics of the subjects studied
are given in Table 1. There was no statistical difference in gen-
der distribution and median age between cases and controls.
At least one marker of HBsAg or anti-HCV was found in
89.81% (97 of 108) of patients with HCC. Cirrhosis was found
in 91 patients (84.25%). The frequency distributions of Child-
Pugh grades A, B, and C in cirrhotic HCC were 43.96%,
39.56%, and 16.48%, respectively.
Polymorphisms in Patients and Controls
The alleles at the TNF-a238 and308 positions in stud-
ied subjects were in accordance with the Hardy-Weinberg
equilibrium (data not shown). Compared to healthy controls,
patients with HCC had a lower frequency of TNF308.1/
TNF308.1 genotype (74.07% vs 92.59%; Pc = .0015) and a
higher frequency of TNF308.1/TNF308.2 genotype (25.00%
vs 7.41%; Pc = .0024). Homozygous TNF308.2/TNF308.2
genotype was found in one HCC patient and in none of con-
trols. Putting together, the frequency of genotypes containing
the TNF308.2 allele in patients (25.93%; 28 of 108) was
higher than that in controls (7.41%; 8 of 108; Pc = .0015). The
frequency of the TNF308.2 allele in HCC patients (13.43%;
29 of 216) was significantly higher than that (3.70%; 8 of 216)
in controls (Pc = .001).
There was no significant difference in the frequency of
TNF238.1/TNF238.2 genotype between patients (5.56%)
and controls (1.85%). There was no homozygous TNF238.2/
TNF238.2 genotype in the subjects studied. The TNF238.2
allele was found in 2.78% (6 of 216) of patients and in 0.93%
(2 of 216) of controls.
Independent Risk Factors for HCC, By Univariate and
Multivariate Analyses
Using healthy controls as a reference group, univariate
analysis indicated that TNF308.2 allele (P = .0015), HBsAg
positivity (P = .0001), and anti-HCV positivity (P = .0001)
were significant risk factors for HCC (Table 2), whereas male
gender, older age (> 50 years), and TNF238.2 allele were
not. Multivariate analysis indicated that TNF308.2 allele
(OR = 3.23; P = .032), HBsAg positivity (OR = 17.47; P =
.0001), and anti-HCV positivity (OR = 45.52; P = .0001) were
independent risk factors for HCC (Table 2).
Clinical Characteristics in HCC Patients, By TNF308.2
Allele Status
As shown in Table 3, all TNF308.2 alleles were found in
patients with cirrhosis (P = .003; Fisher’s exact test). The fre-
quency of carrying the TNF308.2 allele in patients with Child-
Pugh grade A was lower than that in patients with Child-Pugh
grade B (P = .032) or in patients with Child-Pugh grade C
(P = .0002). Moreover, the higher is the Child-Pugh grade,
the higher is the frequency of carrying the TNF308.2 allele
(Pfor trend = .0001). Note that the frequency of carrying the
TNF308.2 allele in patients with anti-HCV alone was higher
Table 1. Basic Characteristics of the Subjects Studied.
Parameters Cases (n = 108) Controls (n = 108)
Gender (male:female) 77:31 77:31
Age in years [median (range)] 52 (32–84) 51 (30–84)
HBsAg/anti-HCV
Negative/negative 11 79
Negative/positive 27 5
Positive/negative 58 24
Positive/positive 12 0
Cirrhosis 91 –
Child-Pugh grade
A 40 –
B 36 –
C 15 –
Tumor–node–metastasis stage of HCC
I 12 –
II 47 –
III (A–C) 45 –
IV 4 –
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than that in patients with HBsAg alone (P = .027). All patients
carrying the TNF308.2 allele had increased serum alanine
aminotransferase (ALT) levels above the upper limit of nor-
mal (P = .003; Fisher’s exact test). There was no significant
difference with regard to gender, older age (> 50 years), and
increased serum levels of a-fetoprotein and aspartate ami-
notransferase (Table 3). Among conventional liver function
tests, the median serum albumin level in patients with the
TNF308.2 allele (3.1 g/dl; range, 2.1–4.1 g/dl) was sig-
nificantly lower than that in those without (3.7 g/dl; range,
2.6–4.4 g/dl; P = .0001). The serum ALT level in the former
(median = 94 IU/l; range, 44–577 IU/l) was significantly higher
than that in the latter (median = 66 IU/l; range, 14–718 IU/l;
P = .025). There was no significant difference with regard to
serum levels of bilirubin, aspartate aminotransferase, alkaline
phosphatase, and g-glutamyl transpeptidase (data not shown).
Surrogate Markers for Hepatic Fibrosis in HCC Patients,
By TNF308.2 Allele Status
As shown in Table 4, TNF308.2 allele carriers tended to
have lower peripheral blood platelet count (P = .0001), worse
prothrombin time (P = .001), and higher levels of AP index
(P = .001), APRI (P = .004), and CDS (P = .0001). Using cut-
off values for significant fibrosis defined by Lackner et al.
[33], the frequency of thrombocytopenia in patients with the
TNF308.2 allele was higher than that in patients not carrying
the TNF308.2 allele (P = .0003). Moreover, the frequencies
of increased AP index, APRI, and CDS values in patients
with the TNF308.2 allele were greater than those in patients
without them (P = .010, P = .003, and P = .0001, respec-
tively). Multivariate analysis indicated that low platelet count
(P = .012), lower serum albumin level (P = .002), and
cirrhosis with Child-Pugh grade C (P = .039) were indepen-
dent risk factors for carrying the TNF308.2 allele (Table 5).
Discussion
Our results indicated that TNF308.2 SNP is an independent
risk factor for HCC (Table 2). Moreover, TNF308.2 SNP is
associated with significant hepatic fibrosis (Table 4) and
more severe liver damage (Tables 3 and 5), which may pre-
dispose to HCC development. This study demonstrated that
host genetic factor (TNF308.2 SNP) plays an important role
in hepatic carcinogenesis.
It has been found that circulating TNF-a levels were
elevated in patients with HCC [44,45]. In the current study,
there was a strong association between TNF308.2 SNP and
risk for HCC (Table 2). Although we did not measure circu-
lating TNF-a levels, TNF308.2 SNP has already been shown
to increase the constitutive and inducible expression of TNF-
a protein [23,24], possibly caused by the differential binding
of a nuclear protein to the TNF308.2 allele [24]. It is reason-
able to speculate that the high circulating TNF-a levels found
in patients with HCC may be attributed to TNF308.2 SNP.
Therefore, this polymorphism could be a causal predisposing
factor for HCC.
Table 2. Risk for HCC, By Univariate and Multivariate Analyses.
Risk Factors Cases
(n = 108)
Controls
(n = 108)
OR
(95% CI)
Adjusted OR*
(95% CI)
TNF308.2 allele
Present 28 8 4.37
(1.78–11.08)
3.23
(1.10–9.44)
Absent 80 100 1.0 1.0
HBsAg
Positive 70 24 6.44
(3.39–12.34)
17.47
(7.82–39.02)
Negative 38 84 1.0 1.0
Anti-HCV
Positive 39 5 11.64
(4.11–35.49)
45.52
(13.23–156.65)
Negative 69 103 1.0
TNF238.2 allele
Present 6 2 3.11
(0.55–24.51)
–
Absent 102 106 1.0
*Adjusted for sex, age > 50 years, HBsAg, anti-HCV, and TNF308.2 allele by
conditional logistic regression analysis.
Table 3. TNF308.2 Allele in Relation to Clinical Parameters in HCC Patients.
Parameters Group n With TNF308.2
Allele [n (%)]
P
Gender Male 77 17 (22.07) NS
Female 31 11 (35.48)
Age (years) V 50 44 9 (20.45) NS
> 50 64 19 (29.68)
Cirrhosis Yes 91 28 (30.76) .003
No 17 0 (0.00)
Child-Pugh A* 40 5 (12.50)y,z .0001
B* 36 13 (36.11)y
C* 15 10 (66.67)z
HBsAg/anti-HCV Negative/negative 11 3 (27.27) NS
Negative/positive 27 12 (44.44)§
Positive/negative 58 11 (18.96)§
Positive/positive 12 2 (16.67)
a-Fetoprotein (ng/ml) V 20 38 11 (28.94) NS
> 20 70 17 (24.28)
AST (IU/l) V 40 (ULN) 16 3 (18.75) NS
> 40 92 25 (27.17)
ALT (IU/l) V 40 (ULN) 19 0 (0.0) .003
> 40 89 28 (31.46)
NS, not significant; ULN, upper limit of normal.
*Pfor trend = .0001 (Mantel extension test for trend).
yOR = 3.95; 95% CI = 1.10–14.89; P = .032.
zOR = 14.00; 95% CI = 2.80–78.00; P = .0002.
§OR = 3.41; 95% CI = 1.12–10.56; P = .027.
Table 4. Surrogate Markers for Hepatic Fibrosis in HCC Patients, By TNF308.2
Allele Status.
Parameter TNF308.2 Allele P
Present (n = 28) Absent (n = 80)
Platelet ( 109 l1) 79 (28–124) 137 (40–390) .0001
Prothrombin time
(international normalized
ratio)
1.2 (1.0–1.5) 1.1 (1.0–1.3) .001
AP index 8 (6–9) 7 (2–8) .001
APRI 2.8 (0.7–20.6) 1.6 (0.3–21.6) .004
CDS 8 (5–18) 6 (0–8) .0001
Thrombocytopenia* (%) 100.0 62.50 .0003
AP index z 6* (%) 100.0 76.25 .010
APRI z 1.5* (%) 82.14 55.00 .003
CDS z 8* (%) 50.00 2.50 .0001
*Cutoff values for significant fibrosis were adapted from Lackner et al. [33].
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Chronic HBV/HCV infection has well been established
as an independent risk factor for HCC [1–4,6–8]. Besides
oncogenic viruses, chronic HBV/HCV infection may lead to
persistent hepatocyte necroinflammation and hepatic fibro-
sis [6,8,11]. Both inflammatory by-products caused by HBV/
HCV infection [13,46,47] and TNF-a derived from activated
Kupffer cells [48] produce oxygen-derived free radicals and
other reactive oxygen species. These compounds are im-
portant mediators of hepatic fibrogenesis in liver injury [27].
Moreover, TNF-a plays an important role in hepatic fibro-
genesis and progression of fibrosis in chronic liver disease
[11,20,27,48–50]. TNF-a may also induce the production of
other fibrogenic factors, such as tumor growth factor-b,
interleukin (IL) 1, and IL-6 [51]. Moreover, both univariate
(Table 4) and multivariate (Table 5) analyses indicated that
among 50% to 100% of our patients with TNF308.2 SNP had
significant hepatic fibrosis. Our results are in consistency
with a previous observation that TNF-a SNP is associated
with advanced hepatic fibrosis [49,50,52], which may con-
tribute to HCC [4,6,8,9,11,27,53,54].
HCC commonly develops in the background of chronic
hepatitis and/or cirrhosis, which, in part, is mediated by cy-
tokines [9]. As shown in Table 1, 84.26% of our HCC patients
had underlying cirrhosis. Serum ALT level is a marker of he-
patic necroinflammation in patients with chronic liver disease
[5]. Sustained abnormal ALT levels in cirrhotic patients are
associated with a higher risk for HCC [3,5]. All patients with
the TNF308.2 allele had cirrhosis (Table 3). Our data in-
dicated that HCC patients with TNF308.2 SNP had more
severe liver damage. In addition, TNF-a may stimulate the
release of other inflammatory cytokines (IL-1, IL-6, IL-8, and
IL-10) that can cause or aggravate liver damage [9,22,23].
Hence, TNF308.2 SNP may aggravate persistent liver inflam-
mation and hepatic injury. Taking all information together, it
is obvious that hepatic fibrosis is a pivotal and necessary
stage to cirrhosis [11,13,20,27,48,53] and/or HCC [4,6,8,27,
37,51,53,54]. TNF308.2 SNP may accelerate the progression
of cirrhosis to HCC owing to its accelerated progression of
hepatic necroinflammation and fibrosis [20,27,48,50].
The current study demonstrated that TNF308.2 SNP is an
independent risk factor for HCC. Our results are consistent
with those previously reported [55], but quite different from
another study [56]. However, one of the shortcomings of this
study is its rather small sample size; therefore, the results
should be confirmed in a larger series, as well as in patients
of different ethic origins. In conclusion, HCC patients with the
TNF308.2 allele had more severe hepatic fibrosis and liver
damage. TNF308.2 SNP correlates with more severe he-
patic fibrosis, which contributes to a higher risk for HCC.
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